Keywords
Hepatic encephalopathy
Hepatorenal syndrome
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: Present, through a case report, the causes, diagnosis, and treatment of liver cirrhosis due to chronic hepatitis C. Case details: A 61-year-old patient with liver cirrhosis secondary to hepatitis C was admitted with hepatic encephalopathy, hepatorenal syndrome, ascites, and urinary tract infection. After being admitted to the intensive care unit and receiving treatment with antibiotics, lactulose, diuretics, albumin, and propranolol, the patient showed progressive improvement in consciousness and renal function, leading to clinical stabilization. The use of lactulose and L-ornithine-L-aspartate was key in controlling the encephalopathy, highlighting the importance of reducing ammonia levels in managing this condition. Final considerations: This case report underscores the complexity of liver cirrhosis, emphasizing the importance of early diagnosis and multidisciplinary management to prevent serious complications and improve prognosis. The treatment partially reversed the symptoms, with successful control of renal function and encephalopathy. Intensive clinical intervention and proper management of comorbidities were crucial for the patient's stabilization and clinical improvement.
References
ASRANI SK, et al. Burden of liver diseases in the world. Journal of Hepatology, 2019; 70(1): 151-171.
BRASIL. MINISTÉRIO DA SAÚDE. Hepatites virais 2023. Boletim Epidemiológico. 2023. Disponível em: https ://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/boletins/epidemiologicos/especiais/2 023/boletim-epidemiologico-de-hepatites-numero-especial-jul.2023. Acessado em: 08 de outubro de 2024.
BRITO IGS, et al. A prevalência de casos de fibrose e cirrose hepática na população brasileira no período entre 2014 a 2018. Brazilian Journal of Development, 2022; 8(5): 37709-37723.
D'AMICO G, et al. Clinical states of cirrhosis and competing risks. Journal of Hepatology, 2018; 68(3): 563-576.
GINÈS P, et al. Liver cirrhosis. Lancet, 2021; 398(10308): 1359-1376.
GONÇALVES BC, et al. Doença hepática gordurosa não alcoólica: evolução e risco de desenvolvimento de cirrose hepática. Revista Eletrônica Acervo Saúde, 2021; 13(5): 1-7.
HUANG DQ, et al. Global epidemiology of cirrhosis – aetiology, trends and predictions. Nature Reviews. Gastroenterology & Hepatology, 2023; 20(6): 388-398.
JACHS M e REIBERGER T. Prevention of variceal bleeding and rebleeding by nonselective beta-blockers: a tailored approach. Clinics in Liver Disease, 2021; 25(2): 311-326.
KASZTELAN-SZCZERBINSKA B e CICHOZ-LACH H. Refractory ascites-the contemporary view on pathogenesis and therapy. PeerJ, 2019; 7: 7855.
KISSINGER PJ, et al. Diagnosis and management of Trichomonas vaginalis: Summary of evidence reviewed for the 2021 centers for disease control and prevention sexually transmitted infections treatment guidelines. Clinical Infectious Diseases, 2022; 74(2): 152-161.
KURATA Y, et al. Effect of liver cirrhosis on theophylline trough concentrations: A comparative analysis of organ impairment using Child-Pugh and MELD scores. British Journal of Clinical Pharmacology, 2022; 88(8): 3819-3828.
LEE NY e SUK KT. The Role of the Gut Microbiome in Liver Cirrhosis Treatment. International Journal of Molecular Sciences, 2020; 22(1): 199.
MARCELLIN P e KUTALA BK. Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening. Liver International, 2018; 38(1): 2-6.
MORAN S, et al. Current approach to treatment of minimal hepatic encephalopathy in patients with liver cirrhosis. World JournalofGastroenterology, 2021; 27(22): 3050-3063.
OLIVEIRA GS, et al. Novas perspectivas no manejo da cirrose: foco na terapia com betabloqueadores não seletivos e o impacto na hipertensão portal. Revista Eletrônica Acervo Saúde, 2023; 23(12): 1-8.
ROEHLEN N, et al. Liverfibrosis: Mechanisticconceptsandtherapeutic perspectives. Cells, 2020; 9(4): 875.
SANTOS IBD, et al. Caracterização clínica-epidemiológica de pacientes com cirrose hepática atendidos em um serviço de referência na Amazônia. Revista Eletrônica Acervo Saúde, 2024; 24(9): 1-10.
SHARMA B e JOHN S. Hepatic Cirrhosis. Stat Pearls Publishing. 2022. Disponível em: https ://www.ncbi.nlm. nih.gov/books/NBK482419. Acessado em: 08 de outubro de 2024.
SMITH A, et al. Cirrhosis: Diagnosis and management. American Family Physician, 2019; 100(12): 759-770.
STREBEL H, et al. Role of brain biomarkers S-100-Beta and neuron-specific enolase for detection and follow-up of hepatic encephalopathy in cirrhosis before, during and after treatment with L-Ornithine-L-Aspartate. GE Portuguese Journal of Gastroenterology, 2020; 27(6): 391-403.
TERRAULT NA, et al. Liver transplantation 2023: Status report, current and future challenges. Clinical Gastroenterology and Hepatology, 2023; 21(8): 2150-2166.
TURCO L, et al. Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension. Liver International, 2023; 43(6): 1183-1194.
YAO L, et al. Mesenchymal stromal cells: promising treatment for liver cirrhosis. Stem Cell Research & Therapy, 2022; 13(1): 308.